SBC · SBC Medical Group Holdings Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $20M | 2Q26 | — |
| Adjusted EBITDA Margin non-GAAP | 41% | 2Q26 | — |
| Average spend per visit | $287 | As of the end of June 2026 | — |
| last-twelve-month number of visits | 6.9M | July 1, 2025 to June 30, 2026 | — |
| number of locations | 287 | As of the end of June 2026 | — |
| ROE (Annualized) | 16% | 2Q26 | — |
| EBITDA non-GAAP | $18M | Q1 2026 | — |
| EBITDA margin non-GAAP | 43% | Q1 2026 | — |
| Number of customers in the last twelve months | 6.76M | Q1 2026 | — |
| Number of franchise locations | 284 | Q1 2026 | — |
| Repeat rate for customers | 72% | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Consulting Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SBC
this stock
SBC Medical Group Holdings Inc
|
$375.39M | -14.6% | -15.5% | — | 0.8% |
|
VRSK
Verisk Analytics, Inc.
|
$24.59B | -16.1% | +6.6% | 28.6 | 3.3% |
|
EFX
Equifax Inc
|
$22.61B | -11.3% | +6.9% | 33.8 | 5.9% |
|
BAH
Booz Allen Hamilton Holding Corp
|
$9.18B | -9.5% | -6.4% | 12.0 | 6.9% |
|
FCN
Fti Consulting, Inc
|
$4.23B | -10.2% | +2.4% | 18.5 | 8.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SBC | +15.4% | +25.6% | -4.7% | +20.3% | -14.6% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +17.3% | +22.3% | -15.8% | +18.2% | -26.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.